Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, January 4, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Raghuram Selvaraju Maintained (ADMA) at Strong Buy with Decreased Target to $11 on, Jan 4th, 2021
Raghuram Selvaraju of HC Wainwright & Co., Maintained "ADMA Biologics, Inc." (ADMA) at Strong Buy with Decreased Target from $12 to $11 on, Jan 4th, 2021.
Raghuram has made no other calls on ADMA in the last 4 months.
There is 1 other peer that has a rating on ADMA. Out of the 1 peers that are also analyzing ADMA, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- Elliot Wilbur of "Raymond James" Maintained at Buy with Decreased Target to $7 on, Thursday, October 1st, 2020
